Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631263 | 0.86 | CYP2D6 (0.56) | CYP2D6OPRL1CHRM2CHRM3CYP3A4 | |
| SCHEMBL21287577 | 0.85 | KMT2A (0.57) | CYP2D6LMNACYP3A4POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL20212096 | 0.84 | POLB (0.56) | CYP2D6OPRL1CHRM2CHRM3CYP3A4 | |
| Hydrochloric Acid SCHEMBL26107522 | 0.84 | POLB (0.56) | CYP2D6LMNAOPRL1CHRM2CHRM3 | |
| SCHEMBL16579978 | 0.84 | CYP2D6 (0.55) | CYP2D6OPRL1CHRM2CHRM3CYP3A4 | |
| Hydrochloric Acid SCHEMBL5766139 | 0.83 | POLB (0.55) | CYP2D6OPRL1CHRM2CHRM3CYP3A4 | |
| SCHEMBL1269458 | 0.81 | CYP2D6 (0.61) | CYP2D6OPRL1CHRM2CHRM3CYP3A4 | |
| SCHEMBL19779408 | 0.80 | KMT2A (0.53) | CYP2D6LMNACYP3A4POLBALDH1A1 | |
| SCHEMBL1771293 | 0.80 | KDM4E (0.53) | CYP2D6LMNAOPRL1CHRM2CHRM3 | |
| SCHEMBL4630748 | 0.80 | CYP2D6 (0.61) | CYP2D6OPRL1CHRM2CHRM3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753941-B1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| CN-115448923-B | Pyrimidine-fused ring compound, preparation method and application thereof | 上海青煜医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-115448923-A | Pyrimido-cyclic compounds, process for their preparation and their use | 青煜医药研发(上海)有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-11-15 | — | — | US | disclosed |
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-11-15 | — | — | US | disclosed |
| CN-110156786-B | Pyrimido-cyclic compounds, process for their preparation and their use | 青煜医药研发(上海)有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3753941-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| EP-3753941-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| CN-110156786-A | Pyrimido-cyclic compounds, process for their preparation and their use | 上海青煜医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| WO-2019158019-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | PTPN11, PPM1F, PTPRF | CYP2D6 2083/4885LMNA 4714/4885OPRL1 4423/4885 |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | PTPN11, PPM1F, PTPRF | CYP2D6 2083/4885LMNA 4714/4885OPRL1 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.